Further developments in radiotracer design and the clinical application of PSMA-targeted RLT in earlier stages of prostate cancer are eagerly awaited to increase the therapeutic options for oncologists and the possible benefit for patients in the near future. Here, FOLH1 is linked to prostate cancer.